Jul. 31 at 12:46 AM
Spartan Capital Securities and B2i Digital are pleased to announce that OS Therapies (NASDAQ:
$OSTX) will be a presenting company at the upcoming Spartan Capital Securities, LLC Investor Conference on November 3rd in New York.
The Spartan Capital Securities, LLC Investor Conference 2025 is a B2i Digital Featured Conference, and OS Therapies is a B2i Digital Featured Company. A complete OSTX company profile is available at https://b2idigital.com/os-therapies-1.
Now in its second year, the Spartan Capital Investor Conference brings together public company executive teams, institutional investors, and thought leaders from across the U.S. capital markets for strategic networking and information exchange. Taking place on November 3rd, 2025, at the Marriott Marquis Hotel in New York, this premier event will welcome 500+ institutional and high-net-worth investors and feature presentations from 60 public and private growth companies across technology, healthcare, consumer, and other high-opportunity sectors. Attendees can expect main-stage presentations, curated one-on-one meetings, and extensive networking opportunities that connect innovative companies with sophisticated capital.
Event details and registration are available at https://b2idigital.com/spartan-capital-investor-conference-2025. B2i Digital is working closely with the outstanding Spartan Capital team, including John D. Lowry (CEO), Kim Monchik (CAO), Stephen Faucetta (Director), and Julia Voss (Executive Assistant), to enhance each presenter’s reach through in-depth digital profiles and targeted outreach.
Investors can register to attend: https://www.meetmax.com/sched/event_125183/investor_reg_new.html?attendee_role_id=SPARTAN_INVESTOR_ATT.
OS Therapies is advancing innovative treatments for osteosarcoma and other challenging cancers under the leadership of CEO Paul Romness and an experienced executive team including Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer). The company’s focused approach aims to deliver potentially transformative therapies for patients facing hard-to-treat malignancies.
Learn more about OS Therapies at https://www.ostherapies.com. For investor inquiries, visit the company’s Investor Relations page or contact
[email protected].
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OSTX stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
